8
Participants
Start Date
September 11, 2024
Primary Completion Date
December 31, 2025
Study Completion Date
March 31, 2026
Siplizumab
Siplizumab is an anti-CD2 monoclonal antibody that has demonstrated a favorable safety profile of siplizumab in over 779 human subjects and has been shown to target memory T cells-a key driver in the immune processes surrounding rejection and autoimmunity post LT in AILD.
RECRUITING
Columbia University Irving Medical Center/NewYork-Presbyterian Hospital, New York
ITB-Med LLC
INDUSTRY
Elizabeth C. Verna
OTHER